EMAP-II Sensitize U87MG and Glioma Stem-like Cells to Temozolomide Via Induction of Autophagy-mediated Cell Death and G2/M Arrest

Overview

Journal Cell Cycle

Specialty Cell Biology

Date 2017 Apr 25

PMID 28436750

Citations 6

Authors

Qi Yu

Libo Liu

Ping Wang

Yilong Yao

Yixue Xue

Yunhui Liu

Affiliations

Soon will be listed here.

Abstract

Despite the fact that temozolomide (TMZ) has been widely accepted as the key chemotherapeutic agent to prolong the survival of patients with glioblastoma, failure and recurrence cases can still be observed in clinics. Glioma stem-like cells (GSCs) are thought to be responsible for the drug resistance. In this study, we investigate whether endothelial monocyte-activating polypeptide-II (EMAP-II), a pro-inflammatory cytokine, can enhance TMZ cytotoxicity on U87MG and GSCs or not. As described in prior research, GSCs have been isolated from U87MG and maintained in the serum-free DMEM/F12 medium containing EGF, b-FGF, and B27. TMZ and/or EMAP-II administration were performed for 72 h, respectively. The results showed that TMZ combined with EMAP-II inhibit the proliferation of U87MG and GSCs by a larger measure than TMZ single treatment by decreasing the IC. EMAP-II also enhanced TMZ-induced autophagy-mediated cell death and G2/M arrest. Moreover, we found that EMAP-II functioned a targeted suppression on mTOR, which may involve in the anti-neoplasm mechanism. The results suggest that EMAP-II could be considered as a combined chemotherapeutic agent against glioblastoma by sensitizing U87MG and GSCs to TMZ.

Citing Articles

Crosstalk between autophagy and CSCs: molecular mechanisms and translational implications.

Li D, Peng X, He G, Liu J, Li X, Lin W Cell Death Dis. 2023; 14(7):409.

PMID: 37422448 PMC: 10329683. DOI: 10.1038/s41419-023-05929-3.

Deciphering the Role of Autophagy in Treatment of Resistance Mechanisms in Glioblastoma.

Khan I, Baig M, Mahfooz S, Rahim M, Karacam B, Elbasan E Int J Mol Sci. 2021; 22(3).

PMID: 33525678 PMC: 7865981. DOI: 10.3390/ijms22031318.

The necessity for standardization of glioma stem cell culture: a systematic review.

Zhang L, Yu H, Yuan Y, Yu J, Lou Z, Xue Y Stem Cell Res Ther. 2020; 11(1):84.

PMID: 32102678 PMC: 7045630. DOI: 10.1186/s13287-020-01589-8.

Quercetin and Sodium Butyrate Synergistically Increase Apoptosis in Rat C6 and Human T98G Glioblastoma Cells Through Inhibition of Autophagy.

Taylor M, Khathayer F, Ray S Neurochem Res. 2019; 44(7):1715-1725.

PMID: 31011879 DOI: 10.1007/s11064-019-02802-8.

Targeting autophagy for combating chemoresistance and radioresistance in glioblastoma.

Taylor M, Das B, Ray S Apoptosis. 2018; 23(11-12):563-575.

PMID: 30171377 PMC: 6193815. DOI: 10.1007/s10495-018-1480-9.

References

Thakkar J, Dolecek T, Horbinski C, Ostrom Q, Lightner D, Barnholtz-Sloan J . Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev. 2014; 23(10):1985-96. PMC: 4185005. DOI: 10.1158/1055-9965.EPI-14-0275. View

Botrugno O, Robert T, Vanoli F, Foiani M, Minucci S . Molecular pathways: old drugs define new pathways: non-histone acetylation at the crossroads of the DNA damage response and autophagy. Clin Cancer Res. 2012; 18(9):2436-42. DOI: 10.1158/1078-0432.CCR-11-0767. View

Kastan M, Bartek J . Cell-cycle checkpoints and cancer. Nature. 2004; 432(7015):316-23. DOI: 10.1038/nature03097. View

Barth S, Glick D, Macleod K . Autophagy: assays and artifacts. J Pathol. 2010; 221(2):117-24. PMC: 2989884. DOI: 10.1002/path.2694. View

Germain M, Nguyen A, Le Grand J, Arbour N, Vanderluit J, Park D . MCL-1 is a stress sensor that regulates autophagy in a developmentally regulated manner. EMBO J. 2010; 30(2):395-407. PMC: 3025469. DOI: 10.1038/emboj.2010.327. View

Liu J, Liu L, Xue Y, Meng F, Li S, Wang P . Anti-neoplastic activity of low-dose endothelial-monocyte activating polypeptide-II results from defective autophagy and G2/M arrest mediated by PI3K/Akt/FoxO1 axis in human glioblastoma stem cells. Biochem Pharmacol. 2014; 89(4):477-89. DOI: 10.1016/j.bcp.2014.04.014. View

Kanzawa T, Germano I, Komata T, Ito H, Kondo Y, Kondo S . Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ. 2004; 11(4):448-57. DOI: 10.1038/sj.cdd.4401359. View

Agarwala S, Kirkwood J . Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist. 2000; 5(2):144-51. DOI: 10.1634/theoncologist.5-2-144. View

Choi E, Cho B, Lee D, Hwang Y, Chun S, Kim H . Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases. BMC Cancer. 2014; 14:17. PMC: 3910677. DOI: 10.1186/1471-2407-14-17. View

10.

Newlands E, Stevens M, Wedge S, Wheelhouse R, Brock C . Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev. 1997; 23(1):35-61. DOI: 10.1016/s0305-7372(97)90019-0. View

11.

Komatsu M, Wang Q, Holstein G, Friedrich Jr V, Iwata J, Kominami E . Essential role for autophagy protein Atg7 in the maintenance of axonal homeostasis and the prevention of axonal degeneration. Proc Natl Acad Sci U S A. 2007; 104(36):14489-94. PMC: 1964831. DOI: 10.1073/pnas.0701311104. View

12.

Johansen T, Lamark T . Selective autophagy mediated by autophagic adapter proteins. Autophagy. 2010; 7(3):279-96. PMC: 3060413. DOI: 10.4161/auto.7.3.14487. View

13.

Vescovi A, Galli R, Reynolds B . Brain tumour stem cells. Nat Rev Cancer. 2006; 6(6):425-36. DOI: 10.1038/nrc1889. View

14.

Meijer A, Codogno P . Regulation and role of autophagy in mammalian cells. Int J Biochem Cell Biol. 2004; 36(12):2445-62. DOI: 10.1016/j.biocel.2004.02.002. View

15.

Polager S, Ofir M, Ginsberg D . E2F1 regulates autophagy and the transcription of autophagy genes. Oncogene. 2008; 27(35):4860-4. DOI: 10.1038/onc.2008.117. View

16.

van Horssen R, Eggermont A, Ten Hagen T . Endothelial monocyte-activating polypeptide-II and its functions in (patho)physiological processes. Cytokine Growth Factor Rev. 2006; 17(5):339-48. DOI: 10.1016/j.cytogfr.2006.08.001. View

17.

Li Z, Liu X, Liu Y, Xue Y, Wang P, Liu L . Roles of Serine/Threonine Phosphatases in Low-Dose Endothelial Monocyte-Activating Polypeptide-II-Induced Opening of Blood-Tumor Barrier. J Mol Neurosci. 2015; 57(1):11-20. DOI: 10.1007/s12031-015-0604-8. View

18.

Esteller M, Garcia-Foncillas J, Andion E, Goodman S, Hidalgo O, Vanaclocha V . Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000; 343(19):1350-4. DOI: 10.1056/NEJM200011093431901. View

19.

Zhang J, Stevens M, Bradshaw T . Temozolomide: mechanisms of action, repair and resistance. Curr Mol Pharmacol. 2011; 5(1):102-14. DOI: 10.2174/1874467211205010102. View

20.

Filatova A, Acker T, Garvalov B . The cancer stem cell niche(s): the crosstalk between glioma stem cells and their microenvironment. Biochim Biophys Acta. 2012; 1830(2):2496-508. DOI: 10.1016/j.bbagen.2012.10.008. View